Immunoadsorbent for purifying five kinds of mycotoxins including fumonisin b1 and aflatoxin b1, and complex affinity column

ABSTRACT

The invention relates to an immunoadsorbent for purifying five kinds of mycotoxins including fumonisin B1 and aflatoxin B1, and a complex affinity column. The immunoadsorbent comprises a solid-phase support, and an anti-fumonisin B1 monoclonal antibody, an anti-aflatoxin B1 monoclonal antibody, an anti-ochratoxin A monoclonal antibody, an anti-zearalenone monoclonal antibody and an anti-sterigmatocystin monoclonal antibody which are coupled to the solid-phase support, wherein the anti-fumonisin B1 monoclonal antibody is secreted by a hybridoma cell strain Fm7A11, and the hybridoma cell strain Fm7A11 has been preserved at China Center for Type Culture Collection, Wuhan University, Wuhan, China on Mar. 29, 2016 with the preservation number of CCTCC No. C201636. The complex affinity column can be used for purification and detection of a fumonisin B1 sample, an aflatoxin B1 sample, an ochratoxin A sample, a zearalenone sample and a sterigmatocystin sample at the same time.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the priority benefit of China application serial No. 201710134052.1, filed on Mar. 7, 2017. The entirety of the above-mentioned patent application is hereby incorporated by reference herein and made a part of this specification.

BACKGROUND OF THE INVENTION 1. Field of the Invention

The invention relates to an immunoadsorbent for purifying five kinds of mycotoxins including fumonisin B₁ and aflatoxin B₁, and a complex affinity column.

2. Description of Related Art

Fumonisins are the water-soluble metabolites produced by Fusaria at a certain temperature and humidity and are a kind of di-ester compounds with similar structures, composed of different polyhydric alcohols and tricarballylic acids. Fumonisins can interfere with the normal physiological functions of plants within a low concentration, are non-enzymatic compounds which have toxic effects on plant metabolism, and belong to mycotoxins and non-host specific toxins. Fumonisins are mainly distributed on such crops as corn, sorghum and wheat, and can cause seedlings blight, decay of roots, stems and seeds as well as other agricultural economic losses. Fumonisins can cause various specific toxicological effects on livestock and laboratory animals, such as leukoencephalomalacia in horses and rabbits. The symptoms are neurotoxicity, disturbance of consciousness, blindness and ataxia, and even death in some severe cases. Fumonisins can also cause pulmonary edema, hydrothorax, and injuries in the liver and esophagus of pigs. Fumonisins can also cause atherosclerosis in primates, hepatocyte apoptosis and nephrotoxicity in rats, lambs and calves, as well as having effect of liver toxicity and carcinogenic, causing serious economic losses to the livestock husbandry.

Aflatoxins are a group of secondary metabolites with similar structures produced by Aspergillus flavus, Aspergillus parasiticus, are a group of compounds with bi-furocoumarins as the basic structure, are widely distributed in cereals, feedstuffs and processed products thereof, and have the highest toxicity and the highest frequency of pollution among two hundred kinds of mycotoxins known at present. Aflatoxins have the effects of inducing mutation, inhibiting immunity and carcinogenesis. Aflatoxin B₁ (AFB₁) is the most toxic and carcinogenic. The main target organ on which AFB₁ acts is liver. AFB₁ is widely recognized as a cause of liver cancer. The liver of people who eat food containing a low level of aflatoxins on a long-term basis will also be damaged. The International Agency for Research on Cancer classified AFB₁ as Group 1 carcinogens.

Ochratoxins are mold nephrotoxins produced by Aspergillus ochraceus and Penicillium verrucosum. Ochratoxins can be divided into two types, ochratoxin A and ochratoxin B, among which ochratoxin A is more toxic. Ochratoxins with toxic concentrations can be produced by Aspergillus ochraceus at the temperature as low as 4. Animal taking 1 ppm of ochratoxin A on the basis of weight dose can die in 5-6 days. Common lesions are renal tubular epithelial damage and intestinal lymphoid necrosis. After feeding animals with a daily feed containing 1 ppm of ochratoxins on the basis of concentration for 3 months, polydipsia, frequent urination and slow growth of animals and decreased feed utilization can be caused. Kidney damage is detectable after feeding animals with a daily feed containing as little as 200 ppb of ochratoxins for weeks. Other clinical symptoms are diarrhea, anorexia and dehydration. Sometimes the clinical symptoms are not obvious, and in areas where ochratoxin poisoning is endemic, the only observable lesions of animals during slaughter are the pale and firm kidneys.

Zearalenone, also known as F-2 toxin, is first isolated from maize with gibberellic disease. The toxigenic bacteria of zearalenone are mainly Fusarium strains such as Fusarium graminearum and Fusarium tricinctum. Zearalenone mainly contaminates maize, wheat, rice, barley, millet, oats and other cereals, among which the positive detection rate of maize is 45%, and the maximum toxic amount can reach 2909 mg/kg. The detection rate of wheat is 20%, and the toxic amount is 0.364-11.05 mg/kg. Zearalenone has high heat resistance, and can only be completely destroyed after being treated at 110° C. for 1 h. Zearalenone has the effects of estrogen, mainly acts on the reproductive system, and can cause estrogen hyperfunction in livestock, poultry and laboratory mice. Gestational animals (including humans) consuming foods containing zearalenone can cause miscarriage, stillbirth and fetal malformation. Various foods made of flour from wheat with gibberellic disease can also cause symptoms of central nervous system poisoning, such as nausea, chills, headaches, mental depression and ataxia.

Sterigmatocystin (ST) is a mycotoxin, and is mainly a secondary metabolite produced by fungi such as Aspergillus versicolor, Aspergillus flavus, Aspergillus nidulans and Aspergillus rugulosus. Sterigmatocystin is widely present in nature. In addition to being metabolically produced in Aspergillus versicolor, Aspergillus flavus and Aspergillus nidulans, sterigmatocystin also widely exists in other molds such as Aspergillus chevalieri, Aspergillus ruber, Aspergillus ustus, Aspergillus amstelodami, Aspergillus quadrilineatus, Aspergillus variecolor and Aspergillus unguis, Chaetomium, Aspergillus aurantio-bruneus and the like. Sterigmatocystin was first isolated from the mycelium of aspergillus versicolor and named by Japanese scholar Yuichi Hatsuda, but did not attract the attention of people at that time. The outbreak of the “turkey X-disease” in the United Kingdom in 1960 was proven that the outbreak was resulted from aflatoxin poisoning, and only since then people started to pay attention on ST which is similar to aflatoxins in structure. In recent years, incidents of chicken, cows, sheep, horses and other livestock in the United Kingdom, Canada, the United States and China die from acute poisoning due to ingestion of ST-containing feed are observed. Animal experiments show that ST can cause liver cancer and lung cancer in animals.

At present, the detection methods of mycotoxins such as fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin are mainly thin-layer chromatography, enzyme-linked immunosorbent assay (ELISA), immunoaffinity chromatography-liquid chromatography, and immunoaffinity chromatography-fluorescence spectrophotometry. Thin-layer chromatography requires contact with a large number of standards, is not good for the health of experimenters, and is low in sensitivity. ELISA is only suitable for qualitative detection, and is prone to false positives and false negatives. Immunoaffinity chromatography-liquid chromatography can quantitatively detect the content of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin in many commercial products. Due to the adoption of advanced biotechnologies, the method can detect the content of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin without the use of toxic solvents such as chloroform and dichloromethane. Therefore, it is imperative to prepare a stable immunoaffinity column and establish an economical, fast, accurate and safe test method.

SUMMARY OF THE INVENTION

In order to solve the problem in the prior art that an immunoaffinity column with stable performance for detecting fumonisin B₁ (FB₁), aflatoxin B₁ (AFB₁), ochratoxin A (OTA), zearalenone (ZEN) and sterigmatocystin (ST) is needed, the present invention provides an immunoadsorbent for purifying fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin, a complex affinity column and a preparation method and application of the complex affinity column.

In order to achieve the above object, the technical scheme adopted by the present invention is:

an immunoadsorbent for purifying fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin comprises a solid-phase support, and an anti-fumonisin B₁ monoclonal antibody, an anti-aflatoxin B₁ monoclonal antibody, an anti-ochratoxin A monoclonal antibody, an anti-zearalenone monoclonal antibody and an anti-sterigmatocystin monoclonal antibody which are coupled to the solid-phase support, wherein the anti-fumonisin B₁ monoclonal antibody is a monoclonal antibody secreted by a hybridoma cell strain Fm7A11 with the preservation number of CCTCC No. C201636, and the hybridoma cell strain Fm7A11 has been preserved at China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China in Mar. 29, 2016 with the preservation number of CCTCC No. C201636.

According to the scheme, the solid-phase support is a sepharose.

A complex affinity column loaded with the immunoadsorbent for purifying fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin.

The complex affinity column for purifying fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin is prepared by the following steps:

(a) preparation of matrix

a CNBr-activated sepharose matrix powder is subjected to washing by HCl at pH 2-3 to remove impurities to obtain a CNBr-activated sepharose matrix;

wherein CNBr-activated sepharose is provided in a lyophilized form, and the additives are washed away with HCl before being coupled to a target ligand at a low pH (pH 2-3) condition;

(b) Ligand coupling

each of the anti-fumonisin B₁ monoclonal antibody, the anti-aflatoxin B₁ monoclonal antibody, the anti-ochratoxin A monoclonal antibody, the anti-zearalenone monoclonal antibody and the anti-sterigmatocystin monoclonal antibody for coupling are dissolved in a coupling buffer to obtain a monoclonal antibody solution, the CNBr-activated sepharose matrix in the step (a) is rapidly transferred to the monoclonal antibody solution to obtain a mixture, and the mixture is thoroughly mixed for 2-4 h at room temperature (20-25° C.);

(c) Ligand blocking

to block all remaining active sites;

(d) removal of uncoupled ligands after the ligand blocking in the step (c); and

(e) column packing.

According to the scheme, the concentration of HCl for the washing in the step (a) is 1 mmol/L and the washing time is 15 min.

According to the scheme, the coupling buffer in the step (b) is 0.2 mol/L NaHCO₃, the pH is 8.3, and the concentration of each of the monoclonal antibody is 10-15 mg/mL.

According to the scheme, the ligand block of the step (c) is conducted by transferring the treated CNBr-activated sepharose matrix treated in the step (b) to a 0.1 mol/L Tris-HCl buffer, and then keep it standing for 2-4 h at room temperature.

According to the scheme, the step (d) is conducted by washing the treated CNBr-activated sepharose matrix treated in the step (c) with a buffer of pH 4 and a buffer of pH 8 in sequence for at least 3 cycles, wherein the buffer of pH 4 is a 0.1 mol/L acetate/sodium acetate buffer with pH of 4, and the buffer of pH 8 is a 0.1 mol/L Tris-HCl buffer with pH of 8.

According to the scheme, the step (e) is conducted by washing with 0.01% NaN₃-PBS with 5 times the volume of the CNBr-activated sepharose matrix in step (d), performing storing with the 0.01% NaN₃-PBS, and then packing the column.

In the scheme, the anti-ochratoxin A antibody may be a monoclonal antibody secreted by a hybridoma cell strain 1H2 with the preservation number of CCTCC No. C201329. The anti-zearalenone antibody may be a monoclonal antibody secreted by a hybridoma cell strain 2D3 with the preservation number of CCTCC No. C201328. The anti-sterigmatocystin antibody may be a monoclonal antibody secreted by a hybridoma cell strain ST03 with the preservation number of CCTCC No. C2013187.

The anti-aflatoxin B₁ monoclonal antibody may be a monoclonal antibody secreted by a hybridoma cell strain 3G1 with the preservation number of CCTCC No. C201014.

The anti-aflatoxin B₁ monoclonal antibody can be replaced by an anti-aflatoxin general monoclonal antibody. Aflatoxin B₁, aflatoxin B₂, aflatoxin G₁ and aflatoxin G₂ can be simultaneously purified by selecting the anti-aflatoxin general monoclonal antibody, and on this basis, co-detection of aflatoxin B₁, aflatoxin B₂, aflatoxins G₁ and aflatoxin G₂ can be achieved.

On this basis, a purification-liquid chromatography-mass spectrometry method for detecting the content of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin by means of the immunoaffinity column is established, when a sample containing fumonisin B₁, aflatoxin, ochratoxin A, zearalenone and sterigmatocystin passes through the complex affinity column, the immunoadsorbent specifically adsorbs fumonisin B₁, aflatoxin, ochratoxin A, zearalenone and sterigmatocystin, other impurities are flowed out from the complex affinity column, then the complex affinity column is eluted with chromatography-grade methanol, fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin are eluted from the column, the flow rate for elution can be 1-2 mL/min, and an eluate, namely the purified and concentrated sample is collected to be detected by a high performance liquid chromatography-mass spectrometer, thereby obtaining the content of the multiple toxins.

A method for detecting the content of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin based on the complex affinity column is provided, when a sample containing fumonisin B₁, aflatoxin, ochratoxin A, zearalenone and sterigmatocystin passes through the immunoaffinity column, the immunoadsorbent specifically adsorbs fumonisin B₁, aflatoxin, ochratoxin A, zearalenone and sterigmatocystin, other impurities flow out of the immunoaffinity column, then the affinity column is eluted with chromatography-grade methanol, and an eluate, namely the purified and concentrated sample is collected to be detected by a high performance liquid chromatography-mass spectrometer, thereby obtaining the content of the multiple toxins.

The conditions of the high performance liquid chromatography-mass spectrometer:

a. mobile phase: A, 0.05% formic acid/water solution; B, 0.05% formic acid/acetonitrile solution

b. gradient elution: 15%-50% B for 0-3 min; 4-5 min, 50%-70% B for 4-5 min; 70%-100% B for 6.5-8 min; 100%-50% B for 8-10 min; 50%-15% B for 10-11 min; and 15% B for 11-15 min.

c. chromatographic column: C-18 column

d. flow rate: 200 μL/min; and

e. the mass spectrometry scanning parameters for various toxins are shown in Table 1.

TABLE 1 Scanning parameters for various toxins Precursor Quantitative Cone Collision ion daughter ions voltage energy Toxin (m/z) (m/z) (V) (V) AFB₁ 313.0 241.0 30 35 [M + H]⁺ 285.0 35 284.9 27 OTA 402.0 166.8 30 [M − H]⁻ 358.1 20 ZEN 317.0 130.8 30 [M − H]⁻ 174.9 25 305.2 30 ST 325.2 115.2 64 [M + H]⁺ 310.1 24 FB₁ 722.05 334.0 35 [M + H]⁺ 352.0 35 265.0 25

The specific quantitative method can be as follows:

a standard working solution containing different concentrations of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin is drawn by a sample injector to be injected into a high performance liquid chromatography-mass spectrometer, high performance liquid chromatogram-mass spectrograms of various toxins and the standard solution peak area of each toxin are obtained under the conditions separately, a standard curve of various toxins is drawn, and an external standard method is used to calculate the content of each toxin.

According to the scheme, the flow rate for elution is 1-2 mL/min.

The affinity column prepared by the method of the present invention can be used for high performance liquid chromatography-mass spectrometry detection of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin and has stable performance. By using the affinity column, an economical, fast, accurate and safe detection method is established, which can be used for the purification of five toxin samples simultaneously without any interference among the five kinds of toxins.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the mass spectrogram-chromatograms of fumonisin B₁ (FB₁), aflatoxin B₁ (AFB₁), ochratoxin A (OTA), zearalenone (ZEN) and sterigmatocystin (ST) in a sample; and from top to bottom the sequence is sterigmatocystin, zearalenone, ochratoxin A, fumonisin B₁, aflatoxin B₁.

DESCRIPTION OF THE EMBODIMENTS Embodiment 1 Example 1: Acquisition of an Anti-Aflatoxin B₁ Monoclonal Antibody

An aflatoxin general monoclonal antibody is secreted by a hybridoma cell strain 3G1 with the preservation number of CCTCC No. C201014, and is prepared in advance according to the method reported in the patent number ZL201210117614.9. The preparation method comprises the steps of injecting the obtained hybridoma cell strain 3G1 into a BALB/c mouse previously treated with a Freund's incomplete adjuvant, collecting the ascites of the mouse and conducting purification to obtain the anti-aflatoxin B₁ monoclonal antibody. The purification method is an octanoic acid-ammonium sulfate method. Specifically, the ascites of the mouse is filtered through double-layer filter paper, the filtered ascites is centrifuged at 4° C. and 12000 r/min for more than 15 min, a supernatant is drawn, the supernatant is mixed with an acetate buffer with 4 times volume, n-octanoic acid is slowly added while stirring, the volume of n-octanoic acid required by per ml of ascites is 30-35 μL, the mixture is mixed at room temperature for 30-60 min and stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a precipitate is discarded, a resulting supernatant is filtered through double-layer filter paper, a phosphate buffer with 1/10 filtrate volume and with a molar concentration of 0.1 mol/L and a pH of 7.4 is added, the pH of the mixed liquid is adjusted with 2 mol/L sodium hydroxide solution to 7.4, precooling is conducted at 4° C., ammonium sulfate is slowly added till the final concentration of ammonium sulfate reaches 0.277 g/mL, the mixture stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a supernatant is discarded, a resulting precipitate is resuspended with 0.01 mol/L phosphate buffer of 1/10 original volume of ascites, placed in a dialysis bag and dialyzed with pure water, the well-dialyzed protein solution is frozen in a −70° C. freezer and then lyophilized with a freezing vacuum dryer, lyophilized powder is collected, thus obtaining the purified anti-aflatoxin B₁ monoclonal antibody, and the antibody is stored in a −20° C. refrigerator for use; and

the acetate buffer is obtained by adding water to 0.29 g of sodium acetate and 0.141 mL of acetic acid to 100 mL; and the 0.1 mol/L phosphate buffer is obtained by adding water to 0.8 g of sodium chloride, 0.29 g of sodium phosphate dibasic dodecahydrate, 0.02 g of potassium chloride and 0.02 g of potassium dihydrogen phosphate to 100 mL.

Example 2: Acquisition of Anti-Ochratoxin A Monoclonal Antibody

An anti-ochratoxin A monoclonal antibody is secreted by a hybridoma cell strain 1H2 with the preservation number of CCTCC No. C201329, and is prepared in advance according to the method reported in the patent number 201310115921.8. The preparation method comprises the steps of injecting the hybridoma cell strain 1H2 into the abdomen of a BALB/c mouse previously treated with a Freund's incomplete adjuvant, collecting the ascites of the mouse and conducting purification to obtain the anti-ochratoxin A monoclonal antibody. The purification method is an octanoic acid-ammonium sulfate method. Specifically, the ascites of the mouse is filtered through double-layer filter paper, the filtered ascites is centrifuged at 4° C. and 12000 r/min for more than 15 min, a supernatant is drawn, the supernatant is mixed with an acetate buffer with 4 times volume, n-octanoic acid is slowly added while stirring, the volume of n-octanoic acid required by per ml of ascites is 30-35 μL, the mixture is mixed at room temperature for 30-60 min and stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a precipitate is discarded, a resulting supernatant is filtered through double-layer filter paper, a phosphate buffer with 1/10 filtrate volume and with a molar concentration of 0.1 mol/L and a pH of 7.4 is added, the pH of the mixed liquid is adjusted with 2 mol/L sodium hydroxide solution to 7.4, precooling is conducted at 4° C., ammonium sulfate is slowly added till the final concentration of ammonium sulfate reaches 0.277 g/mL, the mixture stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a supernatant is discarded, a resulting precipitate is resuspended with 0.01 mol/L phosphate buffer of 1/10 original volume of ascites with a pH of 7.4, placed in a dialysis bag and dialyzed with pure water, the well-dialyzed protein solution is frozen in a −70° C. freezer and then lyophilized with a freezing vacuum dryer, lyophilized powder is collected, thus obtaining the purified anti-ochratoxin A monoclonal antibody, and the antibody is stored in a −20° C. refrigerator for use; and

the acetate buffer is obtained by adding water to 0.29 g of sodium acetate and 0.141 mL of acetic acid to 100 mL; the 0.01 mol/L phosphate buffer is obtained by adding water to 0.8 g of sodium chloride, 0.29 g of sodium phosphate dibasic dodecahydrate, 0.02 g of potassium chloride and 0.02 g of potassium dihydrogen phosphate to 100 mL; and the 0.1 mol/L phosphate buffer is obtained by adding water to 8 g of sodium chloride, 2.9 g of sodium phosphate dibasic dodecahydrate, 0.2 g of potassium chloride and 0.2 g of potassium dihydrogen phosphate to 100 mL.

Example 3: Acquisition of Anti-Zearalenone Monoclonal Antibody

An anti-zearalenone monoclonal antibody is secreted by a hybridoma cell strain 2D3 with the preservation number of CCTCC No. C201328, and is prepared in advance according to the method reported in the patent number 201310115825.3. The preparation method comprises the steps of injecting the hybridoma cell strain 2D3 into the abdomen of a BALB/c mouse previously treated with a Freund's incomplete adjuvant, collecting the ascites of the mouse and conducting purification to obtain the anti-zearalenone monoclonal antibody. The purification method is an octanoic acid-ammonium sulfate method. Specifically, the ascites of the mouse is filtered through double-layer filter paper, the filtered ascites is centrifuged at 4° C. and 12000 r/min for more than 15 min, a supernatant is drawn, the supernatant is mixed with an acetate buffer with 4 times volume, n-octanoic acid is slowly added while stirring, the volume of n-octanoic acid required by per ml of ascites is 30-35 μL, the mixture is mixed at room temperature for 30-60 min and stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a precipitate is discarded, a resulting supernatant is filtered through double-layer filter paper, a phosphate buffer with 1/10 filtrate volume and with a molar concentration of 0.1 mol/L and a pH of 7.4 is added, the pH of the mixed liquid is adjusted with 2 mol/L sodium hydroxide solution to 7.4, precooling is conducted at 4° C., ammonium sulfate is slowly added till the final concentration of ammonium sulfate reaches 0.277 g/mL, the mixture stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a supernatant is discarded, a resulting precipitate is resuspended with 0.01 mol/L phosphate buffer of 1/10 original volume of ascites with a pH of 7.4, placed in a dialysis bag and dialyzed with pure water, the well-dialyzed protein solution is frozen in a −70° C. freezer and then lyophilized with a freezing vacuum dryer, lyophilized powder is collected, thus obtaining the purified anti-zearalenone monoclonal antibody, and the antibody is stored in a −20° C. refrigerator for use; and

the acetate buffer is obtained by adding water to 0.29 g of sodium acetate and 0.141 mL of acetic acid to 100 mL; the 0.01 mol/L phosphate buffer is obtained by adding water to 0.8 g of sodium chloride, 0.29 g of sodium phosphate dibasic dodecahydrate, 0.02 g of potassium chloride and 0.02 g of potassium dihydrogen phosphate to 100 mL; and the 0.1 mol/L phosphate buffer is obtained by adding water to 8 g of sodium chloride, 2.9 g of sodium phosphate dibasic dodecahydrate, 0.2 g of potassium chloride and 0.2 g of potassium dihydrogen phosphate to 100 mL.

Example 4: Acquisition of Anti-Sterigmatocystin Monoclonal Antibody

An anti-sterigmatocystin monoclonal antibody is secreted by a hybridoma cell strain ST03 with the preservation number of CCTCC No. C2013187, and is prepared in advance according to the method reported in the patent number 201410115952.8. The preparation method comprises the steps of injecting the obtained hybridoma cell strain ST03 into the abdomen of a BALB/c mouse previously treated with a Freund's incomplete adjuvant, collecting the ascites of the mouse and conducting purification to obtain the anti-sterigmatocystin monoclonal antibody. The purification method is an octanoic acid-ammonium sulfate purification method. Specifically, the ascites of the mouse is filtered through double-layer filter paper, the filtered ascites is centrifuged at 4° C. and 12000 r/min for more than 15 min, a supernatant is drawn, the supernatant is mixed with an acetate buffer with 4 times volume, n-octanoic acid is slowly added while stirring, the volume of n-octanoic acid required by per ml of ascites is 33 μL, the mixture is mixed at room temperature for 30-60 min and stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a precipitate is discarded, a resulting supernatant is filtered through double-layer filter paper, a phosphate buffer with 1/10 filtrate volume and with a molar concentration of 0.1 mol/L and a pH of 7.4 is added, the pH of the mixed liquid is adjusted with 2 mol/L sodium hydroxide solution to 7.4, precooling is conducted at 4° C., ammonium sulfate is slowly added till the final concentration of ammonium sulfate reaches 0.277 g/mL, the mixture stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a supernatant is discarded, a resulting precipitate is resuspended with 0.01 mol/L phosphate buffer of 1/10 original volume of ascites, placed in a dialysis bag and dialyzed with pure water, the well-dialyzed protein solution is frozen in a −70° C. freezer and then lyophilized with a freezing vacuum dryer, lyophilized powder is collected, thus obtaining the purified anti-sterigmatocystin monoclonal antibody, and the antibody is stored in a −20° C. refrigerator for use; and

the acetate buffer is obtained by adding water to 0.29 g of sodium acetate and 0.141 mL of acetic acid to 100 mL; and the 0.1 mol/L phosphate buffer is obtained by adding water to 0.8 g of sodium chloride, 0.29 g of sodium phosphate dibasic dodecahydrate, 0.02 g of potassium chloride and 0.02 g of potassium dihydrogen phosphate to 100 mL.

Example 5 Acquisition of Anti-Fumonisin B₁ Monoclonal Antibody

Screening of Hybridoma Cell Strain Fm7A11

1. Antigen Synthesis and Animal Immunization

Commercially available fumonisin B₁ standards are purchased for complete antigen synthesis as follows: 2 mg of FB₁ standard powder and 2 mg of EDC are dissolved in 500 μL of a 0.01 mol/L PBS solution respectively to obtain an EDC solution and an FB₁ solution, and 4 mg/mL (0.01 mol/L PBS solution) EDC solution is added dropwise to the solubilized FB₁ solution and gently agitated for 10 min at room temperature. 5 mg/mL of (0.01 mol/L PBS solution) BSA solution is added dropwise to the mixed liquid, and the mixture is stirred at room temperature and reacts for 4 h. Dialysis is conducted for 3 days. Finally, conventional UV scanning identification is conducted, and an identification result shows that FB₁-BSA complete antigen preparation succeeds.

Six 6-week-old BALB/c mice are purchased and immunized with a fumonisin complete antigen FB₁-BSA synthesized in the laboratory. During the first time of immunization, the fumonisin complete antigen and an equal volume of Freund's complete adjuvant are emulsified and then injected subcutaneously into multiple points of the nape of the mice. The second time of immunization is carried out three weeks later. A Freund's incomplete adjuvant and an equal volume of fumonisin complete antigen are emulsified and then injected subcutaneously into multiple points of the nape of the mice. The third time of immunization and the fourth time of immunization are conducted two weeks after the last time of immunization separately, in the same immunization manner as the second time of immunization. The same dose is adopted for four times of immunization, 100 μg per mouse only. On the 7th day after the third time of immunization, blood is collected from the caudal vein of the mice and serum is separated. The serum titer of the mice is monitored through indirect ELISA, the sensitivity of the serum of the mice is measured through indirect competitive ELISA, a mouse corresponding to the serum with higher titer and sensitivity is selected for the final booster immunization, and the immune dose is 2 times the previous dose.

2. Cell Fusion

Three days after the final booster immunization, cell fusion is carried out with a conventional method using 50% (by weight) polyethylene glycol, namely PEG (molecular weight being 1450) as a fusion agent. Specifically, under an aseptic condition, the mice to be fused are killed by breaking the neck, spleen cells are isolated and mixed with murine myeloma cells SP2/0 at a ratio of 5:1, and the mixed cells are washed with an RPMI-1640 basal medium and centrifuged at 1200 rpm for 5 min. A supernatant is discarded, draining is conducted, 1 mL of PEG is added for fusion of 1 min, the RPMI-1640 basal medium is slowly added, centrifugation is conducted, a supernatant is discarded, a precipitation is fusion cells, resuspension is conducted with 20 mL of complete medium, suspended cells are added to 80 mL of semi-solid medium, and the mixture is added to a 6-well cell culture plate after uniform mixing at 2 mL/well, and then placed in a 37° C. CO₂ incubator for culture.

The cell complete medium containing 1% HAT contains 20% (by volume) of fetal calf serum, 75% (by volume) of RPMI-1640 basal medium, 1% (by weight) of L-glutamine, 1% (by volume) of HEPES, 1% (by volume) of double antibody (10,000 units per milliliter of penicillin and 10,000 micrograms per milliliter of streptomycin), 2% (by volume) of growth factor (HFCS) and 1% (by weight) of hypoxanthine-aminopterin-thymidine (HAT) and methylcellulose, the above components are purchased from Sigma-Aldrich Co. Ltd.

3. Cell Strain Screening and Cloning

Two to three weeks after cell fusion, when cell colonies grow to be visible, clones are picked out from the culture medium with a micropipette and transferred to a 96-well cell culture plate to be cultured with HAT liquid, and a culture supernatant is drawn for testing when the cells grow to the position of ⅔ of the well bottom. A two-step screening method is adopted. Indirect ELISA is adopted in the first step to screen out positive wells resistant to fumonisin but not resistant to carrier protein BSA; indirect competitive ELISA is adopted in the second step to detect the positive wells screened out in the first step, fumonisin B₁ is used as a competitive antigen, wells with higher absorbance and sensitivity are chosen (higher absorbance means a higher final measured value for a well with a competitive antigen of 0, namely a positive control well, and higher sensitivity means a smaller competitive antigen concentration, namely IC₅₀ value when the suppression rate is 50%), subcloning is conducted with a limiting dilution method, then the same two-step method is adopted for detection after the subcloning, and subcloning is conducted in the same manner for 4-5 times to obtain a hybridoma cell strain Fm7A11.

4. Anti-Fumonisin B₁ Monoclonal Antibody Hybridoma Cell Strain Fm7A11 Antibody Variable Region Sequence Determination

(1) Total RNA extraction: total RNA capable of producing the hybridoma cell strain Fm7A11 is extracted by using a total RNA extraction kit from TIANGEN according to the instruction manual;

(2) Synthesis of cDNA: a first strand of cDNA is synthesized by reverse transcription according to a SuperScript™-2II reverse transcriptase instruction manual with the total RNA obtained in the step 1 as a template and oligo(dT)15 as a primer, and the primer oligo(dT)15 is purchased from Invitrogen; and

(3) Cloning of variable region genes by PCR: primers are designed according to the conserved sites of mouse antibody gene sequences in GENBANK, to amplify the antibody heavy chain and light chain variable region genes with cDNA as a template. PCR procedures: 94° C. 30 s, 58° C. 45 s, 72° C. 1 min, amplification of 30 cycles, final extension for 10 min at 72° C. After PCR products are subjected to electrophoretic separation by 1% (by weight) sepharose, DNA fragments are purified and recovered with a kit and ligated into a support pMD18-T to be transformed into escherichia coli DH5α competent cells, and positive clones are picked out and sent to Shanghai Sunny Biotechnology Co., Ltd. for sequencing. The sequences of the primers are as follows: the sequences of the primers of the heavy chain variable region are 5′-CAG GTS MAR CTG MAG GAG TCW G-3′ (22mer) and 5′-CAG GGG CCA GTG GAT AGA CAG ATG GGG G-3′ (28mer), wherein S, M, R and W are merging bases, M=A/C, R=A/G, S=G/C, W=A/T, and the sequences of the primers of the light chain variable region are 5′-GAC ATC AAG ATG ACC CAG TCT CCA-3′ (24mer) and 5′-CCG TTT TAT TTC CAG CTT GGT CCC-3′ (24mer).

The obtained gene sequence results: the length of the coding gene sequence of the heavy chain variable region is 379 bp, the sequence is shown in SEQ ID NO: 1, it is deduced from the obtained gene sequence that the heavy chain variable region coded by the gene sequence is composed of 126 amino acids, and the sequence is shown in SEQ ID NO: 3; and the length of the coding gene sequence of the light chain variable region is 348 bp, the sequence is shown in SEQ ID NO: 2, it is deduced from the obtained gene sequence that the light chain variable region coded by the gene sequence is composed of 116 amino acids, and the sequence is shown in SEQ ID NO: 4.

5. Preparation and Purification, Subtypes and Characterization of Anti-Fumonisin B₁ Monoclonal Antibody

The anti-fumonisin B₁ monoclonal antibody hybridoma cell strain Fm7A11 obtained in Example 1 is injected into a BALB/c mouse previously treated with a Freund's incomplete adjuvant, the ascites of the mouse is collected, and the antibody is purified with an octanoic acid-ammonium sulfate method. Specifically, the ascites of the mouse is filtered through double-layer filter paper, the filtered ascites is centrifuged at 4° C. and 12000 r/min for more than 15 min, a supernatant is drawn, the supernatant is mixed with an acetate buffer with 4 times volume, n-octanoic acid is slowly added while stirring, the volume of n-octanoic acid required by per ml of ascites is 30-35 μL, and the mixture is mixed at room temperature for 30-60 min and stands at 4° C. for more than 2 h. Then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a precipitate is discarded, a resulting supernatant is filtered through double-layer filter paper, a phosphate buffer with 1/10 filtrate volume and with a molar concentration of 0.1 mol/L and a pH of 7.4 is added, the pH of the mixed liquid is adjusted with 2 mol/L sodium hydroxide solution to 7.4, ammonium sulfate is slowly added in an ice bath till the final concentration of ammonium sulfate reaches 0.277 g/mL, the mixture stands at 4° C. for more than 2 h, then centrifugation is conducted at 4° C. and 12000 r/min for more than 30 min, a supernatant is discarded, a resulting precipitate is resuspended with 0.01 mol/L phosphate buffer of 1/10 original volume of ascites with a pH of 7.4, placed in a dialysis bag and dialyzed with 0.01 mol/L PBS for two days, then dialysis is conducted with PB for two days, a protein solution in the dialysis bag is taken out and centrifuged, a supernatant is collected, a precipitate is discarded, and then the product is pre-frozen at −70° C. and then lyophilized in a lyophilizer. Lyophilized powder is collected, thus obtaining the purified anti-fumonisin B₁ monoclonal antibody;

the acetate buffer is obtained by adding water to 0.29 g of sodium acetate and 0.141 mL of acetic acid to 100 mL; the 0.01 mol/L phosphate buffer is obtained by adding water to 0.8 g of sodium chloride, 0.29 g of sodium phosphate dibasic dodecahydrate, 0.02 g of potassium chloride and 0.02 g of potassium dihydrogen phosphate to 100 mL; and the 0.1 mol/L phosphate buffer is obtained by adding water to 8 g of sodium chloride, 2.9 g of sodium phosphate dibasic dodecahydrate, 0.2 g of potassium chloride and 0.2 g of potassium dihydrogen phosphate to 100 mL.

The subtype of the anti-fumonisin B₁ monoclonal antibody secreted by the hybridoma cell strain Fm7A11 is identified as IgG2b by using a commercially available subtype identification kit.

The titer of the antibody obtained by purifying the ascites of the mouse is measured to be 3.2×10⁵ through conventional non-competitive enzyme-linked immunosorbent assay (ELISA), that is to say, a solution measurement result is positive when the antibody is diluted by 3.2×10⁵ times. The sensitivity to fumonisin B₁ is measured to be 0.32 ng/mL through conventional indirect competitive ELISA. The cross-reactivities to fumonisins B₂ and B₃ are 4.3% and 12.8%. Cross-reactivities with aflatoxin, zearalenone, T-2 toxin, ochratoxin and vomitoxin are all less than 0.1%.

Embodiment 2

Preparation of Fumonisin B₁, Aflatoxin B₁, Ochratoxin A, Zearalenone and Sterigmatocystin Complex Immunoaffinity Column

1. Preparation of Matrix

1 g of sepharose lyophilized matrix powder required (3.5 mL of swelling matrix of final volume can be obtained from per gram of lyophilized matrix powder) is weighed and the sepharose lyophilized matrix powder is dissolved in 1 mmol/L HCl. The matrix will swell immediately and is then placed in a sintered glass filter to be washed with 1 mmol/L HCl for 15 min.

2. Ligand (Antibody) Coupling

a. The anti-fumonisin B₁ monoclonal antibody, the anti-aflatoxin B₁ monoclonal antibody, the anti-ochratoxin A monoclonal antibody, the anti-zearalenone monoclonal antibody and the anti-sterigmatocystin monoclonal antibody for coupling are dissolved by using a coupling buffer of 0.2 mol/L NaHCO₃ with a pH of 8.3, wherein the concentration of each antibody is 12.5 mg/mL, and the dissolved antibodies are placed in an ice bath for temporary storage. The antibody-containing coupling buffer is added to a capped container capable of being completely sealed. CNBr activated sepharose is rapidly transferred to the antibody solution. The mixture is thoroughly mixed for 2-4 h at the room temperature (20-25° C.).

b. Calculation of the coupling rate: centrifugation is conducted at 2,000 rpm till sepharose is centrifuged to the bottom of a tube, a supernatant is transferred to a new centrifuge tube, and the protein content of the supernatant is measured. The coupling rate is calculated to be 98.5% (indicating that coupling is successful). The sepharose centrifuged to the bottom of the tube is taken out and washed with the coupling buffer to remove excess ligands.

c. Block: the matrix is transferred to a 0.1 mol/L Tris-HCl buffer. The matrix in the 0.1 mol/L Tris-HCl buffer stands for 2-4 h at room temperature to block all remaining active sites.

d. In order to remove uncoupled unwanted ligands after coupling, the matrix is washed with buffers with a pH of 4 and a pH of 8, namely, 0.1 mol/L acetate/sodium acetate buffer and 0.1 mol/L Tris-HCl buffer in sequence for at least 3 cycles, wherein the usage amount of each buffer is at least 5 times the volume of the matrix. Each washing cycle comprises the steps of conducting washing with the 0.1 mol/L acetate/sodium acetate buffer first and then with the 0.1 mol/L Tris-HCl buffer.

e. Washing is conducted with 5 times the colloidal volume of 0.01% NaN₃-PBS and storage is conducted with 0.01% NaN₃-PBS.

3. Column loading: a slurry is prepared by combining with and using the buffer, and 75% of sedimenting matrix and 25% of phosphate buffer (pH 7.0) are mixed; the slurry is poured into the column continuously; a glass rod leaning against the inner wall of the column is used for column packing, which will help reduce the generation of air bubbles; after column packing, an opening in the lower end of the affinity column is closed and a top part of the affinity column is taken down; the remaining portion of the affinity column is carefully filled with a PBS buffer with a pH of 7.0 to form an upward meniscus at the top end of the affinity column; a top sieve plate is inserted into the affinity column at a certain angle to ensure that there is no air under the sieve plate; the sieve plate is locked at a proper position of the surface of the matrix, an opening in the bottom of the affinity column is opened, 0.01% NaN₃-PBS for sterile filtration with 5 times column bed volume passes through the column, and storage is conducted with 0.01% NaN₃-PBS, thereby completing loading and balancing of the fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin affinity column so that the affinity column can be directly used.

Embodiment 3: Detection of Fumonisin B₁, Aflatoxin B₁, Ochratoxin A, Zearalenone and Sterigmatocystin in Rice

1.0 Detection of Fumonisin B₁, Aflatoxin B₁, Ochratoxin a, Zearalenone and Sterigmatocystin in Rice

Rice adding recovery experiments: fumonisin B₁ with the concentration gradient of 500 μg/kg, 1000 μg/kg and 2000 μg/kg, and aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin with the concentration gradients of 10 μg/kg, 20 μg/kg and 50 μg/kg are added respectively. Five groups of parallel tests are made for each experiment.

Three Gradients:

The dose for the first experiment: 500 μg/kg of fumonisin B₁, 10 μg/kg of aflatoxin B₁, 10 μg/kg of ochratoxin A, 10 μg/kg of zearalenone and 10 μg/kg of sterigmatocystin.

The dose for the second experiment: 1000 μg/kg of fumonisin B₁, 20 μg/kg of aflatoxin B₁, 20 μg/kg of ochratoxin A, 20 μg/kg of zearalenone and 20 μg/kg of sterigmatocystin.

The dose for the third experiment: 2000 μg/kg of fumonisin B₁, 50 μg/kg of aflatoxin B₁, 50 μg/kg of ochratoxin A, 50 μg/kg of zearalenone and 50 μg/kg of sterigmatocystin.

Extraction of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin in rice:

20.0 g of ground sample (particle size being less than 2 mm) is weighed accurately in a homogenizer, 100 mL of acetonitrile/water/formic acid (80+18+2) is added, and homogenization, high-speed stirring and extraction are conducted for 2 min. Quantitative filter paper filtration: 5.0 mL of filtrate is accurately transferred, 15.0 mL of PBS solution with a PH of 7.0 is added for dilution, and filtration is conducted with glass fiber filter paper for 1-2 times till filtrate becomes clear. The complex immunoaffinity column is attached to the bottom of a 10.0 mL glass syringe. 10.0 mL of sample extract is accurately transferred into the glass syringe, an air pressure pump and the glass syringe are connected, and the pressure is adjusted to enable the solution to slowly pass through the complex immunoaffinity column at a flow rate of about 6 mL/min until 2-3 mL of air passes through the column. The column is eluted twice with 10.0 mL of water, all eluate is discarded, and 2-3 mL of air is made to pass through the column. 1.0 mL of chromatography-grade methanol is accurately added for elution, the flow rate is 1-2 mL/min, and all eluate is collected in a glass test tube for testing.

2.0 High Performance Liquid Chromatography-Mass Spectrometry Conditions

a. Mobile phase: A, 0.05% formic acid/water solution; B, 0.05% formic acid/acetonitrile solution

b. Gradient elution: 0-3 min, 15%-50% B; 4-5 min, 50%-70% B; 6.5-8 min, 70%-100% B; 8-10 min, 100%-50% B; 10-11 min, 50%-15% B; and 11-15 min, 15% B.

c. Chromatographic column: C-18 column (column length 50 mm, inner diameter 2.1 mm, packing diameter 1.7 μm)

d. Flow rate: 200 μL/min and

e. The mass spectrometry scanning parameters for various toxins are shown in Table 1.

3.0 Quantification

A standard working solution containing different concentrations of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin is drawn by a sample injector to be injected into a high performance liquid chromatography-mass spectrometer, high performance liquid chromatogram-mass spectrograms of various toxins and the standard solution peak area of each toxin are obtained under the conditions separately, a standard curve of each toxin is drawn, and an external standard method is used to calculate the content of each toxin.

4.0 Results

The results of the adding standard recovery for rice are between 85%-105% with RSD less than 10%. The results show that the method completely meets the analysis requirement for detecting fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin in rice. The results are shown in Table 1-Table 5 respectively.

TABLE 1 Recovery results of fumonisin B₁ in rice Spiked concentration of fumonisin B₁ Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 500 104.1 99.3 101.3 99.5 96.7 2.7 1000 86.8 92.3 86.4 87.5 98.3 5.6 2000 93.5 104.6 86.7 97.7 92.5 7.0

TABLE 2 Recovery results of aflatoxin B₁ in rice Spiked concentration of aflatoxin B₁ Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 98.6 90.9 91.5 86.7 100.5 6.1 20 103.4 93.3 87.6 87.6 90.6 7.1 50 87.6 101.1 98.4 93.5 102.4 6.3

TABLE 3 Recovery results of ochratoxin A in rice Spiked concentration of ochratoxin A Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 92.5 91.2 87.7 103.1 98.8 6.5 20 88.4 91.1 100.9 92.3 86.9 5.9 50 95.6 103.4 96.8 102.2 98.4 3.4

TABLE 4 Recovery results of zearalenone in rice Spiked concentration of zearalenone Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 88.8 90.6 95.5 97.6 102.7 5.9 20 90.4 93.8 85.6 94.4 100.8 6.0 50 103.6 100.7 89.7 88.8 98.6 6.9

TABLE 5 Recovery results of sterigmatocystin in rice Spiked concentration of sterigmatocystin Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 100.8 100.2 92.7 99.6 95.4 3.6 20 93.3 99.9 101.6 99.7 103.5 3.9 50 89.7 94.4 96.6 102.5 93.2 5.0

Embodiment 4: Detection of Fumonisin B₁, Aflatoxin B₁, Ochratoxin A, Zearalenone and Sterigmatocystin in Edible Oil

1.0 Detection of Fumonisin B₁, Aflatoxin B₁, Ochratoxin A, Zearalenone and Sterigmatocystin in Edible Oil

Edible oil adding standard recovery experiments: fumonisin B₁ with the concentration gradient of 500 μg/kg, 1000 μg/kg and 2000 μg/kg, and aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin with the concentration gradients of 10 μg/kg, 20 μg/kg and 50 μg/kg are added respectively. Five groups of parallel tests are made for each experiment.

Extraction of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin in edible oil:

vegetable oil liquid sample extraction: 5.0 g of vegetable oil sample is weighed accurately in a 50 mL centrifuge tube, 15.0 mL of 70% aqueous methanol is added, oscillation blending is conducted in a vortex mixer for 2 min, centrifugation is conducted at 5000 r/min for 2 min, 10.0 mL of methanol solution layer is transferred, dilution is conducted with 20.0 mL of water, uniform mixing is conducted in a mixer, and filtration is conducted with glass fiber filter paper till filtrate becomes clear. The complex immunoaffinity column is attached to the bottom of a 10.0 mL glass syringe. 10.0 mL of sample extract is accurately transferred into the glass syringe, an air pressure pump and the glass syringe are connected, and the pressure is adjusted to enable the solution to slowly pass through the complex immunoaffinity column at a flow rate of about 6 mL/min until 2-3 mL of air passes through the column. The column is eluted twice with 10.0 mL of water, all eluate is discarded, and 2-3 mL of air is made to pass through the column. 1.0 mL of chromatography-grade methanol is accurately added for elution, the flow rate is 1-2 mL/min, and all eluate is collected in a glass test tube for testing.

2.0 High Performance Liquid Chromatography-Mass Spectrometry Conditions

a. Mobile phase: A, 0.05% formic acid/water solution; B, 0.05% formic acid/acetonitrile solution

b. Gradient elution: 0-3 min, 15%-50% B; 4-5 min, 50%-70% B; 6.5-8 min, 70%-100% B; 8-10 min, 100%-50% B; 10-11 min, 50%-15% B; and 11-15 min, 15% B.

c. Chromatographic column: C-18 column (column length 50 mm, inner diameter 2.1 mm, packing diameter 1.7 μm)

d. Flow rate: 200 μL/min and

e. The mass spectrometry scanning parameters for various toxins are shown in Table 1.

3.0 Quantification

A standard working solution containing different concentrations of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin is drawn by a sample injector to be injected into a high performance liquid chromatography-mass spectrometer, high performance liquid chromatogram-mass spectrograms of various toxins and the standard solution peak area of each toxin are obtained under the conditions separately, a standard curve of each toxin is drawn, and an external standard method is used to calculate the content of each toxin.

4.0 Results

The results of the adding recovery for vegetable oil are between 85%-105% with RSD less than 10%. The results show that the method completely meets the analysis requirement for detecting fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin in edible oil. The results are shown in Table 6-Table 10 respectively.

TABLE 6 Recovery results of fumonisin B₁ in vegetable oil Spiked concentration of fumonisin B₁ Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 500 92.3 91.6 101.5 88.3 97.2 5.5 1000 104.1 103.4 92.8 90.8 93.4 6.5 2000 97.5 85.8 97.5 91.7 100.5 6.2

TABLE 7 Recovery results of aflatoxin B₁ in vegetable oil Spiked concentration of aflatoxin B₁ Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 90.5 103.2 103.1 89.7 95.3 6.8 20 90.6 102.1 94.8 99.8 89.4 5.8 50 98.1 88.5 101.1 102.5 90.6 6.5

TABLE 8 Recovery results of ochratoxin A in vegetable oil Spiked concentration of ochratoxin A Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 87.2 102.5 91.8 90.1 96.9 6.5 20 89.8 94.4 99.7 90.6 89.1 4.8 50 87.7 91.6 98.7 89.3 102.2 6.7

TABLE 9 Recovery results of zearalenone in vegetable oil Spiked concentration of zearalenone Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 96.5 103.1 85.8 86.3 102.2 8.8 20 88.4 89.1 91 99.5 102.1 6.7 50 102.5 105.7 101.8 102.2 89.9 6.1

TABLE 10 Recovery results of sterigmatocystin in vegetable oil Spiked concentration of sterigmatocystin Recovery Recovery Recovery Recovery Recovery μg/kg rate 1 % rate 2 % rate 3 % rate 4 % rate 5 % RSD % 10 97.3 96.7 94.9 87.9 86.7 5.4 20 90.5 99.1 103.1 89.7 95.6 5.9 50 94.7 90.5 99.4 103.3 104.4 5.9 

What is claimed is:
 1. An immunoadsorbent for purifying fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin, comprising a solid-phase support, and an anti-fumonisin B₁ monoclonal antibody, an anti-aflatoxin B₁ monoclonal antibody, an anti-ochratoxin A monoclonal antibody, an anti-zearalenone monoclonal antibody and an anti-sterigmatocystin monoclonal antibody which are coupled to the solid-phase support, wherein the anti-fumonisin B₁ monoclonal antibody is secreted by a hybridoma cell strain Fm7A11, and the hybridoma cell strain Fm7A11 has been preserved at China Center for Type Culture Collection, Wuhan University, Wuhan, China on Mar. 29, 2016 with the preservation number of CCTCC No. C201636.
 2. The immunoadsorbent according to claim 1, wherein the solid-phase support is a sepharose.
 3. A complex affinity column loaded with the immunoadsorbent according to claim for purifying fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin.
 4. A preparation method of the complex affinity column according to claim 3, comprising the following steps: (a) preparation of matrix a CNBr-activated sepharose matrix powder is subjected to washing by HCl at pH 2-3 to remove impurities to obtain a CNBr-activated sepharose matrix; (b) ligand coupling each of the anti-fumonisin B₁ monoclonal antibody, the anti-aflatoxin B₁ monoclonal antibody, the anti-ochratoxin A monoclonal antibody, the anti-zearalenone monoclonal antibody and the anti-sterigmatocystin monoclonal antibody for coupling are dissolved in a coupling buffer to obtain a monoclonal antibody solution, the CNBr-activated sepharose matrix in the step (a) is rapidly transferred to the monoclonal antibody solution to obtain a mixture, and the mixture is thoroughly mixed for 2-4 h at room temperature (20-25° C.); (c) ligand blocking to block all remaining active sites; (d) removal of uncoupled ligands after the ligand blocking in the step (c); and (e) column packing.
 5. The preparation method according to claim 4, wherein concentration of the HCl for the washing in the step (a) is 1 mmol/L and the washing time is 15 min.
 6. The preparation method according to claim 4, wherein the coupling buffer in the step (b) is 0.2 mol/L NaHCO₃, pH 8.3, and concentration of each of the monoclonal antibody is 10-15 mg/mL.
 7. The preparation method according to claim 4, wherein the ligand blocking of the step (c) is conducted by transferring the treated CNBr-activated sepharose matrix in the step (b) to a 0.1 mol/L Tris-HCl buffer, and then keep it standing for 2-4 h at room temperature.
 8. The preparation method according to claim 4, wherein the step (d) is conducted by washing the treated CNBr-activated sepharose matrix in the step (c) with a buffer of pH 4 and a buffer of pH 8 in sequence for at least 3 cycles, wherein the buffer of pH 4 is a 0.1 mol/L acetate/sodium acetate buffer with pH of 4, and the buffer of pH 8 is a 0.1 mol/L Tris-HCl buffer with pH of
 8. 9. The preparation method according to claim 4, wherein the step (e) is conducted by washing with 0.01% NaN₃-PBS with 5 times volume of the CNBr-activated sepharose matrix, storing with the 0.01% NaN₃-PBS, and then packing the column.
 10. A method for detecting content of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin with the complex affinity column according to claim 3, wherein when a sample containing fumonisin B₁, aflatoxin, ochratoxin A, zearalenone and sterigmatocystin passes through the complex affinity column, the immunoadsorbent specifically adsorbs fumonisin B₁, aflatoxin, ochratoxin A, zearalenone and sterigmatocystin, other impurities are flowed out from the complex affinity column, followed by elution of the complex affinity column with chromatography-grade methanol to obtain an eluate, and the eluate, namely the purified and concentrated sample is collected and subjected to detection by a high performance liquid chromatography-mass spectrometer, thereby obtaining the content of fumonisin B₁, aflatoxin B₁, ochratoxin A, zearalenone and sterigmatocystin. 